Dabrafenib
|
|
|
- CAS-Nr.
- 1195765-45-7
- Englisch Name:
- Dabrafenib
- Synonyma:
- Dabrafenib (GSK2118436);N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;CS-658;abrafenib;Darafenil;Dabrafenib;Darla fini;GSK2118436A;Debrafenib API
- CBNumber:
- CB32604230
- Summenformel:
- C23H20F3N5O2S2
- Molgewicht:
- 519.56
- MOL-Datei:
- 1195765-45-7.mol
|
Dabrafenib Eigenschaften
- Schmelzpunkt:
- 214-216oC
- Siedepunkt:
- 653.7±65.0 °C(Predicted)
- Dichte
- 1.443
- storage temp.
- -20°C
- L?slichkeit
- Soluble in DMSO (up to 30 mg/ml with warming), or in Ethanol (up to 1 mg/ml with warming).
- Aggregatzustand
- White solid.
- pka
- 6.62±0.10(Predicted)
- Farbe
- Off-white
- Stabilit?t:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
- InChIKey
- BFSMGDJOXZAERB-UHFFFAOYSA-N
- SMILES
- C1(S(NC2=CC=CC(C3=C(C4C=CN=C(N)N=4)SC(C(C)(C)C)=N3)=C2F)(=O)=O)=C(F)C=CC=C1F
Dabrafenib Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
In May 2013, the US FDA approved dabrafenib (also referred to as GSK 2118436) for the treatment of patients with unresectable or metastatic melanoma with the BRAF
V600E mutation as detected by a FDA-approved test. Dabrafenib was identified from a screen of an oncology-directed kinase collection, followed by extensive structure–activity relationships (SAR) on an initial thiazole lead. Dabrafenib is a potent inhibitor of B-BRAF
V600E kinase (IC
50=0.65 nM) compared to its potency against wild-type B-raf (IC
50=3.2 nM). It also inhibits other kinases (e.g., CRAF) and other mutant B-raf kinases (BRAF
V600E and BRAF
V600D) with enzyme IC
50s of <5 nM and is fairly selective versus a panel of 270 kinases. Consistent with its in vitro activity, oral administration of dabrafenib inhibits the growth of B-Raf
V600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts growing subcutaneously in immunocompromised mice. Key steps in the synthesis of dabrafenib are condensation of an aryl sulfonamide ester with the lithium anion of 2-chloro-4-methylpyrimidine to generate a ketone intermediate and bromination of the ketone intermediate with N-bromosuccinamide followed by cyclization with tert-butyl thioamide to afford the desired thiazole core.
Verwenden
Dabrafenib is an inhibitor of mutated BRAF kinase and has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.
Definition
ChEBI: An organofluorine compound and antineoplastic agent, used as its mesylate salt in treatment of metastatic melanoma.
Allgemeine Beschreibung
Class: dual threonine/tyrosine kinase;
Treatment: melanoma with BRAF mutations; Oral bioavailability = 95%;
Elimination half-life = 8 h;
Protein binding = 99.7%
Dabrafenib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Dabrafenib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 292)Lieferanten
- Dabrafenib
- Dabrafenib free base(GSK2118436A)
- GSK2118436A
- Dabrafenib (GSK2118436A)
- Dabrafenib
KB-57246
- Debrafenib API
- BenzenesulfonaMide, N-[3-[5-(2-aMino-4-pyriMidinyl)-2-(1,1-diMethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-
- N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
- Dabrafenib N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
- N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide Dabrafenib
- Dabrafenib Base
- Dabrafenib(GSK2118436)
KB-57246
- Dabrafenib, >=98%
- GSK2118436, Dabrafenib, GSK2118436A
- Dabrafenib(free base)
- Debrafenib free base
- N-(3-(5-(2-Aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenes
- CS-658
- Dabrafenib, 98%, a mutant BRAFV600 specific inhibitor
- GSK2118436A (Dabrafenib)
- GSK2118436A (DABRAFENIB);GSK-2118436B (DABRAFENIB MESYLATE);GSK-2118436A;GSK-2118436;GSK2118436A;GSK2118436A;GSK 2118436;GSK 2118436
- GSK-2118436B (Dabrafenib Mesylate)
- Dabrafenib USP/EP/BP
- n-(3-(5-(2-amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl)-...
- N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
- Dabrafenib (GSK2118436)
- N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
- Darla fini
- Dapafenib impurities
- GSK-2118436,inhibit,GSK 2118436,Dabrafenib,Raf kinases,Inhibitor,Raf
- abrafenib
- N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide
- Darafenil
- 1195765-45-7
- 115765-45-7
- C23H20F3N5O2S2
- Inhibitors
- inhibitor
- MAPK
- Raf B protein kinase inhibitor
- API
- API
- 1195765-45-7
